Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial

Trial Profile

Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2015

At a glance

  • Drugs Sorafenib (Primary) ; Doxorubicin
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms SoraDox
  • Most Recent Events

    • 31 Mar 2014 Planned end date changed from 1 Oct 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 31 Mar 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 25 Jan 2013 Planned end date changed from 1 Sep 2012 to 1 Oct 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top